• Nurix Therapeutics is advancing with its oral BTK degrader, bexobrutideg, showing a 80.9% ORR in phase 1a data for CLL treatment.
• Stifel Nicolaus has set a price target of $33 for NRIX, indicating a significant potential upside from its current price.
• The company plans to initiate a pivotal phase 2 study in late 2025, targeting a multibillion-dollar market with its innovative cancer therapies.

Nurix Therapeutics, trading under the symbol (NASDAQ:NRIX), is a biotechnology company focused on developing innovative therapies for cancer treatment. The company is making strides with its oral BTK degrader, bexobrutideg, targeting chronic lymphocytic leukemia (CLL). This progress has led to a Strong Buy rating, as the company plans to initiate a pivotal phase 2 study in late 2025.

Stifel Nicolaus has set a price target of $33 for NRIX, significantly higher than its current price of $9.76. This target suggests a potential upside of approximately 238%. The stock has seen a decrease of 10.13%, with a change of $1.10, reflecting market volatility. Despite this, the company's market capitalization remains robust at $750.3 million.

Nurix's phase 1a data for bexobrutideg shows an impressive 80.9% overall response rate (ORR), supporting the potential for Accelerated Approval. The company aims to expand its efforts with a phase 3 trial and explore combination therapies for CLL. This strategy targets a multibillion-dollar market, offering significant growth opportunities.

The stock has fluctuated between $9.50 and $10.56 today, with a 52-week high of $29.56 and a low of $8.18. The trading volume stands at 1,996,408 shares, indicating active investor interest. As Nurix advances its clinical programs, the stock's performance will likely be influenced by upcoming trial results and market developments.